SMTL ID : 9lvv.1

Crystal structure of SARS-CoV-2 3CL protease in complex with compound 17 (S-892216)

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 1.90 Å

Oligo State

monomer

Ligands

1 x 01: 1-(2-azanylideneethyl)-6-[6,6-bis(fluoranyl)-2-azaspiro[3.3]heptan-2-yl]-5-(3-chloranyl-4-fluoranyl-phenyl)-3-(5-chloranylpyridin-3-yl)pyrimidine-2,4-dione

01.1: 20 residues within 4Å: Chain A: T.27, L.29, H.43, C.46, T.47, S.48, M.51, F.142, L.143, N.144, G.145, S.146, C.147, H.165, H.166, M.167, E.168, D.189, R.190, Q.191 7 PLIP interactions: 7 interactions with chain A Hydrophobic interactions: A:M.167 Hydrogen bonds: A:G.145, A:C.147, A:E.168 Water bridges: A:T.28 pi-Stacking: A:H.43 Halogen bonds: A:T.27

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Unoh, Y. et al., Discovery of The Clinical Candidate S-892216: A Second-Generation of SARS-CoV-2 3CL Protease Inhibitor for Treating COVID-19. To Be Published

Release Date

2025-05-14

Peptides

3C-like proteinase: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

3C-like proteinase

Related Entries With Identical Sequence